

# Gopal Krishna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3910293/publications.pdf>

Version: 2024-02-01

10  
papers

93  
citations

1478280

6  
h-index

1372474

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

79  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 891-898.	1.1	21
2	Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 899-906.	1.1	13
3	Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 461-473.	1.1	11
4	Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 941-952.	1.1	10
5	Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 307-314.	1.1	9
6	Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 87-95.	1.1	9
7	A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 995-1001.	1.1	6
8	Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 369-377.	1.1	5
9	Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1109-1117.	1.1	5
10	Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 366-375.	0.8	4